SCHEMBL22310341

SCHEMBL22310341

O=c1ccc2c([nH]1)sc1ccc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 0.41
PIM2 Q9P1W9 3/20 0.41
EPM2A O95278 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.39
METAP2 P50579 1/20 0.36
CHEK1 O14757 1/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
ABL1 P00519 1/20 0.36
NTRK1 P04629 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
MET P08581 1/20 0.36
PDGFRB P09619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22310755 0.76 EPM2A (0.40) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL9404642 0.73 PIM1 (0.41) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL29432245 0.73 EPM2A (0.53) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL216673 0.73 EPM2A (0.53) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL6238353 0.70 PIM1 (0.44) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL1993262 0.70 EPM2A (0.47) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL10227293 0.70 EPM2A (0.44) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL29466898 0.70 KDM4E (0.48) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL27709221 0.70 EPM2A (0.51) PIM1PIM2EPM2APTPN2PTPN1
SCHEMBL5019781 0.70 KDM4E (0.48) PIM1PIM2EPM2APTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056559-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2023-02-23 US disclosed
EP-3919492-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR Medshine Discovery Inc. (CN) 2021-12-08 EP disclosed
WO-2020156453-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR 南京明德新药研发有限公司 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056559-A1 PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR MET, MYC, METAP1 PIM1 208/4885PIM2 195/4885EPM2A 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.